Richard Furman, MD
Enriched profileMorton Coleman, M.D. Distinguished Professor of Medicine; Director, CLL Research Center, Division of Hematology and Oncology, Weill Cornell Medicine · Weill Cornell Medicine
Richard Furman is Morton Coleman, M.D. Distinguished Professor of Medicine; Director, CLL Research Center, Division of Hematology and Oncology, Weill Cornell Medicine at Weill Cornell Medicine. OpenAlex indexes 506 publications with 33,491 citations (h-index 76); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Richard Furman, MD, is Morton Coleman, M.D. Distinguished Professor of Medicine at Weill Cornell Medicine (Weill Cornell Medical College, Cornell University). The public record shows 506 publications with 33,491 citations (h-index 76), centered on Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Immunodeficiency and Autoimmune Disorders. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 17 companies.
- Most recent indexed publication: 2026 · Leukemia
- Top research focus: Chronic Lymphocytic Leukemia Research
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 245.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL
Sponsor: Weill Medical College of Cornell University
- Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL
Sponsor: Weill Medical College of Cornell University
- Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
Sponsor: Weill Medical College of Cornell University
Industry payments
Updated 14 Oct 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- BeOne Medicines USA, Inc.Program year20259 payments
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- ABBVIE INC.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
67.9%Kinase inhibitor46.5%Brukinsa58%Jaypirca42%Part D≥33 patientsBCL-2 Inhibitor13%Venclexta100%Part D≥16 patients+ 2 more classes in this area
Anti-infectives
21.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor16.7%Valacyclovir100%Part D≥23 patientsShort-acting sulfonamides5.2%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsMusculoskeletal
5.9%Xanthine oxidase inhibitor5.9%Allopurinol100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
105 congress contributions (2004–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Outcome comparison of once versus twice daily dosing of zanubrutinib.
ASCO Annual Meeting
ASCO2026Co-author - Co-mapping clonal and transcriptional heterogeneity in somatic evolution via got-multi.
ASH Annual Meeting
ASH2025Co-author - Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry.
Blood cancer journal
Article2025 - Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
Blood advances
Article2024 - XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.
Cancer research
Article2024
Most-cited works
by citation count (OpenAlex)- 01Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaArticle2,264 citations2013
- 02Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaArticle1,691 citations2014
- 03Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaArticle1,631 citations2014
- 04Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeArticle1,575 citations2013
- 05Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor IbrutinibArticle1,262 citations2014
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/richard-furman-md-9f1388c7
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/richard-furman-243657250
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/in/richard-furman-aa2343110
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Richard-R-Furman-38521873
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
cllsociety.org/2024/05/ask-me-anything-featuring-dr-richard-furman-and-jeff-folloder
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cllsociety.org ↗ - Other
cornell-lymphoma.com/tag/richard-furman-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cornell-lymphoma.com ↗ - Other
news.weill.cornell.edu/people/dr-richard-furman
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.weill.cornell.edu ↗ - Other
onclive.com/authors/richard-r-furman-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Other
vjhemonc.com/speaker/richard-furman
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗ - YouTube
youtube.com/user/weillcornelllymphoma/videos
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
- Board Certified
American Board of Internal Medicine (Internal Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗ - Board Certified
American Board of Internal Medicine (Hematology)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗ - Board Certified
American Board of Internal Medicine (Medical Oncology)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
Secondary affiliations
appointments beyond the home institution- Associate Attending Physician
NewYork-Presbyterian Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
Media & interviews
press, podcasts and appearances- Regular video contributor/interviewee
OncLive oncology news platform, discussing CLL treatment (e.g. "Dr. Furman on Current Treatment Options in CLL")
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Jedd Wolchok, MD
Weill Cornell Medicine
Ronald Crystal, MD
Weill Cornell Medicine
Robert Harrington, MD
Weill Cornell Medicine
Giuseppe Giaccone, MD, PhD
Weill Cornell Medicine
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center